CompletedNCT03692910
A Study to Evaluate SAGE-217 in Participants With Bipolar I/II Disorder With a Current Major Depressive Episode
This study evaluated the safety and effectiveness of SAGE-217 for people with bipolarity.
Medication studyAges 18–65United States
Understand this study
What did researchers investigate?
This study evaluated the safety and effectiveness of SAGE-217 for people with bipolarity.
Who was this study for?
This study was for people with type I bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Little Rock and 10 more locationsSee all locations and recruitment
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Study information
Study start dateStarted: August 23, 2018
- Recruitment status
- Completed
- Enrollment listed in the registry
- 35
- Sponsor
- Biogen
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT03692910
- Official title
Show the full official title
A 2-Part Study (Open-label Followed by Double-blind, Randomized, Placebo-controlled, Parallel Group) of the Safety, Tolerability, Pharmacokinetics, and Efficacy of SAGE-217 in the Treatment of Subjects With Bipolar I/II Disorder With a Current Major Depressive Episode
Get this study by email
Recruitment & locations
CompletedLittle Rock · Garden Grove · Lemon Grove
8 more locations
- Orange
- Jacksonville
- Lauderhill
- Orlando
- Decatur
- St Louis
- Austin
- Richardson
Questions about this study
What did researchers investigate?
This study evaluated the safety and effectiveness of SAGE-217 for people with bipolarity.
Who is behind this study?
The study sponsor is Biogen.
Did this study involve medication?
Yes. The study involved medication, including SAGE-217 and Placebo.
Who was this study for?
This study was for people with type I bipolarity. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
